Merus B.V.

General Information

We are a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics. Our pipeline of full-length human bispecific antibody candidates, which we refer to as Biclonics, are generated from our technology platform. By binding to two different targets, Biclonics can be designed to simultaneously block receptors that drive tumor cell growth and survival and to mobilize the patient’s immune response by activating various killer cells to eradicate tumors.

Employees: 45
Founded: 2003
Contact Information
Address Padualaan 8 (postvak 133), 3584 CH Utrecht, the Netherlands
Phone Number +31 30 253 8800
Web Address
View Prospectus: Merus B.V.
Financial Information
Market Cap $154.0mil
Revenues $2.3 mil (last 12 months)
Net Income $-26.4 mil (last 12 months)
IPO Profile
Symbol MRUS
Exchange NASDAQ
Shares (millions): 5.5
Price range $10.00 - $10.00
Est. $ Volume $55.0 mil
Manager / Joint Managers Citigroup/ Jefferies
CO-Managers Guggenheim Securities/ Wedbush PacGrow
Expected To Trade: 5/19/2016
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change